ArticleBlood2018
High-grade B-cell lymphoma with
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
17.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 1 synthesis or guideline pooled it, 238 citations in OpenAlex.
- A Diagnostic Approach in Large B-Cell Lymphomas According to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice.International journal of molecular sciences · 2024Guideline
- Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.The Lancet. Haematology · 2018Trial
- AI for prognostic assessment of diffuse large B-cell lymphoma using H&E whole-slide images.HemaSphere · 2026Article
- Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.British journal of haematology · 2026Article
- Clinical and Pathological Features That Predict High-Grade B-Cell Lymphomas (HGBCLs) withBiomedicines · 2026Review
- Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit.Histopathology · 2026Article
- Baseline Lactate Dehydrogenase Predicts Early Treatment Failure in Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Real-World Cohort Study.Journal of clinical medicine research · 2026Article
- Double-hit primary high-grade gastric B-cell lymphoma presenting with pancytopaenia and atraumatic back pain: A case report.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Burkitt Lymphoma-A Guide to Biological Features, Diagnosis and Differential Diagnosis.Cancers · 2026Review
- SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell Lymphomas.Clinical lymphoma, myeloma & leukemia · 2026Review
- Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.Blood advances · 2026Article
- Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition.Clinical epigenetics · 2026Article
- Interim efficacy and preliminary survival outcomes of polatuzumab vedotin in combination for diffuse large B-cell lymphoma: a retrospective real-world study.Frontiers in oncology · 2026Article
- HGBL-NOS presenting as widespread extranodal disease without lymphadenopathy: a case report.Frontiers in oncology · 2026Article
- Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.Frontiers in immunology · 2026Review
- Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.Molecular biomedicine · 2025Article
- Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms?Hematology. American Society of Hematology. Education Program · 2025Review
- High-grade B-cell lymphomas: high difficulties to diagnose and treat?Hematology. American Society of Hematology. Education Program · 2025Review
- The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis.NPJ precision oncology · 2025Review
- Racial Differences in the Molecular Genetic Biomarkers of Diffuse Large B-Cell Lymphoma.Biomedicines · 2025Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 7 institutions in 3 countries.
David W ScottCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Rebecca L KingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Annette M StaigerDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Susana Ben-NeriahCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Aixiang JiangDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, Canada.
Heike HornDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany.
Anja MottokCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Pedro FarinhaCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Graham W SlackCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Daisuke EnnishiCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Norbert SchmitzDepartment of Medicine, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Michael PfreundschuhDepartment of Medicine, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Grzegorz S NowakowskiDepartment of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
Brad S KahlDepartment of Oncology, Mayo Clinic, Rochester, MN; and.
Joseph M ConnorsCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
Randy D GascoyneCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
William R MaconDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Andreas RosenwaldInstitute of Pathology, Würzburg University and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Washington University in St. Louis · USBC Cancer Agency · CAMayo Clinic in Arizona · USDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DERobert Bosch Hospital · DESaarland University · DEUniversity of British Columbia · CA
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MWashington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6MNaional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
$6.6MNational Clinical Trials Network Research at the University of WisconsinU10CA180799 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ANDERSON, BETHANY M, KUSHNER, DAVID M · 2014 to 2018
$2.8MNCI NIH HHS U10 CA180790NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180799NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180833NCI NIH HHS U24 CA196172
Abstract
High-grade B-cell lymphoma with
Indexed as
Gene RearrangementCell Line, TumorHumansIn Situ Hybridization, FluorescenceLymphoma, Large B-Cell, DiffuseNeoplasm GradingProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-myc
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.